AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.
Pharmaceutical Technology on MSN
NICE greenlights Pfizer’s Talzenna for NHS use
NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.
Corrosion inhibitors market to grow from $9.15 B in 2024 to $13.03 B by 2033, registering a 4.01% CAGR amid rising ...
Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many ...
PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.
Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial ...
Zacks Investment Research on MSN
Why Merck's 32% rally isn't enough to change the bearish view
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
Milestone follows disclosure of compelling preliminary data presented at the ESMO Congress and the CTOS 2025 Annual Meeting showing clinically meaningful anti-tumor activity in desmoid tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results